Hereditary non-polyposis colorectal cancer (HNPCC) is a very important clinical entity in oncology. In order to identify HNPCC, the international diagnostic criteria named 'Amsterdam criteria' have been used. In this report, we present a case of an HNPCC patient who met the revised Amsterdam criteria after the sequential history taking in which a novel germline mutation of hMSH2 gene was detected by genetic testing. The proband was a 69-year-old Japanese female who was admitted to our hospital with a diagnosis of advanced ascending colon cancer. Microsatellite instability (MSI) analysis revealed high MSI in the resected tumor tissue. PCR/direct sequencing analysis of the genomic DNA revealed the TTG(Leu) to TAG(Stop) nonsense mutation at codon 302 in exon 5 of the hMSH2 gene, which was considered to be a pathogenic mutation. According to the Human Mutation Database and International Collaborative Group on HNPCC (ICG-HNPCC) Database, this type of nonsense mutation is the first report in the hMSH2 gene.
GENETICS SUMMARY

Disorder:
Hereditary non-polyposis colorectal cancer Ethnicity of patient: Japanese Gene: hMSH2 GenBank accession number: U04045 Chromosomal assignment: 2p21 Type of DNA variant:
A germline nonsense mutation Mutation:
Base transversion of TTG(Leu) to TAG(Stop) at codon 302 in exon 5 of the hMSH2 gene Type of DNA variant:
A germline missense mutation (polymorphism) Mutation:
Base transition of ATA(Ile) to GTA(Val) at codon 169 in exon 3 of the hMSH2 gene Method of mutation detection:
RT-PCR/direct sequencing and PCR/direct sequencing
CASE REPORT AND GENETIC ANALYSIS
Hereditary non-polyposis colorectal cancer (HNPCC) is a very important clinical entity because of its clinical characteristics such as relatively high frequency (1.0-5.0%) among all colorectal cancers and relatively early onset of malignancies in various organs, etc. (1) . In order to identify HNPCC, the international diagnostic criteria named 'Amsterdam minimum criteria' were proposed in 1991 and have been used thereafter. However, at least three colorectal cancer patients in the pedigree were needed to fulfil these criteria. Moreover, considering the variety of malignancies other than colorectal cancer occur-ring in HNPCC families, this might miss some proportion of true HNPCC. Therefore, a revised version of these criteria, 'Amsterdam criteria II' was proposed in 1999. In this report, we present a case of an HNPCC patient who met the revised Amsterdam criteria after the sequential history taking in which a novel germline mutation of hMSH2 gene was detected by genetic testing. The proband was a 69-year-old Japanese female who was admitted to Kansai Rosai Hospital with a diagnosis of advanced ascending colon cancer. Right hemicolectomy was carried out in January 2002. A histopathological diagnosis of moderately differentiated adenocarcinoma of clinical stage Duke's C was made.
The initial history taking was done at the outpatient's clinic and revealed that the patient had a history of operation for intestinal obstruction and her mother had died with duodenal cancer and a younger sister with an operation history for uterine cancer, although the details of these histories were unknown. These data prompted us to check the microsatellite instability (MSI) status of the tumor tissue to investigate further the possibility of HNPCC. As shown in Fig. 1 , MSI analysis revealed that among five microsatellite markers used, four (D2S136, D3S1067, D18S51 and BAT26) were positive, resulting in high MSI in the tumor tissue. This result, taken together with the patient's history, further suggested that the patient might be HNPCC kindred and made us ask again about the past and family history, and we finally were able to obtain the precise history as shown in Fig. 2 , indicating that the patient was HNPCC and completely fulfilled the revised Amsterdam criteria. With written informed consent, genetic testing was carried out using DNA extracted from the proband's peripheral lymphocytes. As the result, two possible mutations were detected by long RT-PCR/direct sequencing analysis and PCR/ direct sequencing analysis. One was the ATA(Ile) to GTA(Val) missense mutation at codon 169 in exon 3 of the hMSH2 gene. This mutation had been confirmed to be detected in one out of 100 normal DNAs in Japanese and was considered as the rare polymorphism seen in the Japanese population. The other was the TTG(Leu) to TAG(Stop) nonsense mutation at codon 302 in exon 5 of the hMSH2 gene and was considered to be a significant functional mutation in the disease. Representative profiles of germline DNA analysis are shown in Figures 3  and 4 . No mutation was detected in the hMLH1 gene.
The family in this report had been considered to be an HNPCC family who met the revised Amsterdam criteria after the sequential history taking and the genetic testing confirmed the diagnosis. A search of the Human Mutation Database and International Collaborative Group on HNPCC (ICG-HNPCC) Database indicated that this TTG(Leu) to TAG(Stop) nonsense mutation at codon 302 in exon 5 of the hMSH2 gene has not been reported previously and this is considered to be the first case. The mutation detected in the proband was most likely to be derived from her mother, who had died with duodenal cancer at the age of 98 years. If so, it is considered that this mutation was not able to cause any other malignancies in her mother for as long as 98 years. This is intriguing as the same mutation might have caused the advanced colon cancer in the proband at the age of 36 years. In order to confirm that the mutation detected in this report was truly disease-causing mutation, further genetic analysis of the family members, especially the proband's sister with a history of endometrial cancer, was needed. Also, career diagnosis in this family might be clinically useful and beneficial for each family member. However, the proband did not want the result disclosed to herself, and therefore further genetic analysis has not been undertaken so far.
METHODS FOR MUTATION DETECTION
Fluorescence-based PCR was performed with the following conditions and parameters for identification of MSI and LOH on four dinucleotide markers, as described previously (2,3): PCR primers for chromosome 2p (D2S136 locus):
Forward: 5¢-AGCTTGAGACCTCTTGTGTCC-3¢ Reverse: 5¢-ATTCAGAAGAAACAGTGATGGT-3¢ Size of PCR product: 95 bp PCR primers for chromosome 3p (D3S1067 locus):
Forward: 5¢-TCATCTATCTCCCAACTGTTGAG-3¢ Reverse: 5¢-GAGCACTACCTGTTTAAGATAGG-3¢ Size of PCR product: 95 bp PCR primers for chromosome 17p (TP53 locus):
Forward: 5¢-ACTGCCACTCCTTGCCCCATTC-3¢ Reverse: 5¢-AGGGATACTATTCAGCCCGAG-3¢ Size of PCR product: 118 bp PCR primers for chromosome 18q (D18S51 locus):
Forward: 5¢-CCGACTACCAGCAACAACAC-3¢ Reverse: 5¢-CATGCCACTGCACTTCACTC-3¢ Size of PCR product: 278 bp Reverse primers were labeled with 6-FAM (2p), TET (3p), HEX (17p) or TAMRA (18q) and non-labeled forward primers for the above four regions were synthesized. 
